CN113229503A - Probiotic solid beverage for construction personnel in closed environment and preparation method and application thereof - Google Patents
Probiotic solid beverage for construction personnel in closed environment and preparation method and application thereof Download PDFInfo
- Publication number
- CN113229503A CN113229503A CN202110117866.0A CN202110117866A CN113229503A CN 113229503 A CN113229503 A CN 113229503A CN 202110117866 A CN202110117866 A CN 202110117866A CN 113229503 A CN113229503 A CN 113229503A
- Authority
- CN
- China
- Prior art keywords
- solid beverage
- vitamin
- closed environment
- probiotic solid
- construction personnel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 69
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 69
- 235000013361 beverage Nutrition 0.000 title claims abstract description 49
- 239000007787 solid Substances 0.000 title claims abstract description 49
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 48
- 238000010276 construction Methods 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 19
- 239000011782 vitamin Substances 0.000 claims abstract description 16
- 235000013343 vitamin Nutrition 0.000 claims abstract description 16
- 229940088594 vitamin Drugs 0.000 claims abstract description 16
- 229930003231 vitamin Natural products 0.000 claims abstract description 16
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 30
- 229920001100 Polydextrose Polymers 0.000 claims description 15
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 15
- 239000001259 polydextrose Substances 0.000 claims description 15
- 229940035035 polydextrose Drugs 0.000 claims description 15
- 235000013856 polydextrose Nutrition 0.000 claims description 15
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 9
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 9
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 9
- 239000011691 vitamin B1 Substances 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- 239000011716 vitamin B2 Substances 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 206010049565 Muscle fatigue Diseases 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 description 16
- 238000012360 testing method Methods 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000007413 intestinal health Effects 0.000 description 4
- 229940057917 medium chain triglycerides Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 235000021062 nutrient metabolism Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000168254 Siro Species 0.000 description 1
- IHBCFWWEZXPPLG-UHFFFAOYSA-N [Ca].[Zn] Chemical compound [Ca].[Zn] IHBCFWWEZXPPLG-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Non-Alcoholic Beverages (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Hematology (AREA)
Abstract
The embodiment of the invention relates to the technical field of functional foods, and particularly relates to a probiotic solid beverage for construction personnel in a closed environment, and a preparation method and application thereof. The probiotic solid beverage for construction personnel in the closed environment comprises 15-25g of medium-chain triglyceride, 8-15g of prebiotics, 300-800 hundred million CFU of probiotics and 10-25mg of vitamins in parts per day. The prepared probiotic solid beverage can reduce body fatigue score, total fatigue score and body fat rate of sealed environment constructors by taking medium-chain triglyceride, prebiotics, probiotics and vitamins as main raw materials, so that the muscle fatigue of the sealed environment constructors is remarkably relieved.
Description
Technical Field
The invention relates to the technical field of functional foods, in particular to a probiotic solid beverage for construction personnel in a closed environment, and a preparation method and application thereof.
Background
The engineering project of the closed environment refers to the implementation of exploration, excavation, exploitation and engineering construction in caves and underground, such as national defense strategic construction, subway and tunnel construction, mineral exploration and exploitation and the like. The engineering project has special environment and great difference with the outside, and is mainly characterized by poor air circulation, insufficient sunlight, large relative humidity, higher concentration of toxic and harmful gases and dust, easy transmission of pathogenic microorganisms, strong noise and the like. These adverse factors can easily cause fatigue, pain in waist and legs, and bowel dysfunction of the construction personnel in the closed environment, and harm the life safety of the operation personnel. In the past, the labor and physical strength of constructors are gradually reduced, so that the delay of the engineering progress and the reduction of the engineering quality are easily caused, and even safety accidents are caused seriously. Although the innovation of engineering machinery, the upgrade of protective equipment and the construction safety education management all provide certain guarantee for the safety and health of engineering operators, the research on the aspect of nutrition supply for the health guarantee of the operators is fresh.
In recent years, the market of probiotic solid beverages is rapidly growing, and the probiotic solid beverages have the advantages of promoting intestinal health, maintaining the balance of intestinal flora, regulating immunity and the like and are receiving wide attention. However, most of the probiotic solid beverages are directed to middle-aged and elderly people and sportsmen, and no probiotic solid beverage is suitable for construction personnel in a closed environment. Due to the influence of various factors such as long working time, high working strength, poor working environment and the like, the ordinary probiotic solid beverage is difficult to adjust. Therefore, the probiotic solid beverage for the construction personnel in the closed environment is provided in a targeted manner, the muscle fatigue of the construction personnel can be relieved, the life safety of the working personnel is guaranteed, and the probiotic solid beverage has important significance.
The information disclosed in this background section is only for enhancement of understanding of the general background of the invention and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person skilled in the art.
Disclosure of Invention
Object of the Invention
In order to solve the problems, the invention aims to provide a probiotic solid beverage for construction personnel in a closed environment, and a preparation method and application thereof. The probiotic solid beverage can obviously reduce body fatigue, total fatigue and body fat rate, and relieve muscle fatigue of constructors in a closed environment.
Solution scheme
In order to achieve the purpose of the invention, the embodiment of the invention provides the following technical scheme:
a probiotic solid beverage for construction personnel in a closed environment comprises 15-25g of medium-chain triglyceride, 8-15g of prebiotics, 300-800 hundred million CFU of probiotics and 10-25mg of vitamins in parts per day.
In one possible implementation mode, the probiotic solid beverage for the closed environment constructor comprises 18-22g of medium-chain triglyceride, 9-12g of prebiotics, 300-800 hundred million CFU of probiotics and 17-23mg of vitamins in daily parts.
In one possible implementation, the probiotic solid beverage for the closed environment constructor comprises 20g of medium-chain triglyceride, 10g of prebiotics, 600 hundred million CFU of probiotics and 22mg of vitamin in daily portion.
In one possible implementation, the medium chain triglycerides have a fat content of 70.0 g/100 g or more, caprylic acid (C8:0) at 50.0% or more based on total fat, and capric acid (C10:0) at 25.0% or more based on total fat; the water content is less than or equal to 2.0 percent.
In one possible implementation, the prebiotic is one or more of fructo-oligosaccharide, xylo-oligosaccharide, and polydextrose.
In one possible implementation, the probiotic is a mixture of lactobacillus acidophilus, lactobacillus gasseri and lactobacillus paracasei.
In one possible implementation, the vitamin is vitamin B1Vitamin B2Vitamin B6Vitamin B12One or more of (a).
In one possible implementation mode, the probiotic solid beverage for the closed environment constructor comprises the following formula components in parts per day: 20g of medium chain triglyceride, Lactobacillus gasseri 200 hundred million CFU, 200 hundred million CFU of lactobacillus acidophilus, 200 hundred million CFU of lactobacillus paracasei, 2g of fructo-oligosaccharide, 6g of polydextrose, 2g of xylo-oligosaccharide and vitamin B110mg of vitamin B 22 mg; vitamin B 610 mg; vitamin B12 100μg。
In one possible implementation mode, the medium chain triglyceride is prepared by a conventional method in the prior art, vegetable oil and medium chain triglyceride are used as raw materials, ester exchange reaction is carried out by lipase, and the medium chain triglyceride is obtained after distillation separation, decoloration, deodorization and spray drying.
A preparation method of probiotic solid beverage for construction personnel in closed environment comprises the steps of premixing and mixing, wherein the premixing comprises the steps of mixing probiotics, vitamins and part of polydextrose according to content to obtain premix A, and mixing the rest polydextrose, xylooligosaccharide, fructooligosaccharide and medium-chain triglyceride to obtain premix B; the mixing is to uniformly mix the premix A and the premix B.
In a possible implementation mode, the preparation method of the probiotic solid beverage for the construction personnel in the closed environment further comprises the steps of checking and accepting raw materials and auxiliary materials and weighing before premixing; after mixing, the steps of inspection, gold inspection, packaging, inspection and warehousing are also included in sequence.
In one possible implementation mode, the raw and auxiliary materials are required to be operated in a clean area before being checked and accepted to be packaged; the apparatus is preferably a conical dry blending apparatus.
Probiotic solid beverage for construction personnel in closed environment and application of preparation method thereof in food, health care products and medicines.
Advantageous effects
(1) In the embodiment of the invention, the inventor provides a probiotic solid beverage for construction personnel in a closed environment. The probiotic solid beverage takes medium-chain triglyceride, prebiotics, probiotics and vitamins as raw materials, and effectively relieves fatigue of constructors in a closed environment through the synergistic effect of bioactive substances with functional components. Wherein the synergistic effect of the probiotics and the prebiotics is more beneficial to improving the intestinal health and promoting the energy metabolism and the nutrient metabolism; the intestinal health is inseparable from the probiotics and prebiotics, which have a synergistic effect on each other, while the use has a better effect on the intestinal health than the use of probiotics or prebiotics alone, due to the synergistic effect between live probiotics and a specific selective substrate, i.e. prebiotics. The prebiotics are used as food of probiotics in intestinal tract, promote the growth and reproduction of beneficial bacteria, and inhibit the growth of harmful bacteria. The probiotics and the prebiotics supplement each other and play a role together to improve the immunity of the human body. The medium chain triglyceride can directly reach the liver through the portal vein without passing through the lymphatic system, and directly enter mitochondria to carry out beta oxidation without depending on the action of carnitine, thereby providing energy for cells. The digestion and absorption are fast, the energy is easy to release, and the fat accumulation is reduced while the energy is provided. Vitamins maintain energy metabolism and maintain the physiological functions of the nervous system. The immunity is improved and the anti-fatigue effect is achieved by limiting the daily intake of different raw materials in the solid beverage.
(2) In the embodiment of the invention, the medium-chain triglyceride and other components in the probiotic solid beverage can be matched with each other by limiting the composition proportion of the medium-chain triglyceride, so that the anti-fatigue effect of constructors is further improved.
(3) In the embodiment of the invention, the prebiotics are fructo-oligosaccharide, polydextrose and xylo-oligosaccharide. The fructo-oligosaccharide has low heat energy value, and has the advantages of preventing dental caries, promoting proliferation of lactobacillus, reducing cholesterol and triglyceride in serum, and preventing and treating diarrhea and constipation; the polydextrose can regulate lipid metabolism, reduce cholesterol, reduce sugar absorption, and prevent and treat constipation; the xylo-oligosaccharide has the advantages of reducing the generation of toxic fermentation products and harmful bacterial enzymes, inhibiting pathogenic bacteria and diarrhea, preventing constipation, protecting liver function, reducing serum cholesterol, lowering blood pressure, enhancing immunity of organism, resisting cancer, etc. In addition, the xylooligosaccharide has obvious multiplication effect on bacillus. The prebiotics selected by the invention interact with the probiotics to promote the proliferation of the probiotics and the energy metabolism and nutrient metabolism.
Drawings
FIG. 1 is a process flow diagram of a method for preparing a probiotic solid beverage according to the present invention;
fig. 2 is a comparative sensory evaluation graph of probiotic solid beverages prepared in example 1, example 2 and example 3.
Deposit description
Lactobacillus gasseri: the preservation number is CGMCC No.19749, the product is preserved in China general microbiological culture Collection center (CGMCC) at 27 days 4 and 4 months 2020, the address is No. 3 Siro-1 Hospital, Beijing, the south Kogyo, and the detection result is survival;
lactobacillus acidophilus: the preservation number is CGMCC No.1084, the product is preserved in China general microbiological culture Collection center (CGMCC) at 1 month and 6 days in 2004, the address is No. 3 Siro No.1 Hospital, Beijing, and the detection result is survival.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are a part of the embodiments of the present invention, but not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Furthermore, in the following detailed description, numerous specific details are set forth in order to provide a better understanding of the present invention. It will be understood by those skilled in the art that the present invention may be practiced without some of these specific details. In some embodiments, materials, elements, methods, means, and the like that are well known to those skilled in the art are not described in detail in order to not unnecessarily obscure the present invention.
Throughout the specification and claims, unless explicitly stated otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or component but not the exclusion of any other element or component.
In the examples of the invention, the oligomerization usedFructose, xylo-oligosaccharide and vitamin B1Vitamin B2Vitamin B6Vitamin B12And the lactobacillus paracasei are conventional commercial products. Medium chain triglycerides were purchased from biosciences, inc.
Example 1.
A probiotic solid beverage for construction personnel in sealed environment comprises Lactobacillus gasseri 2.0 × 10 in parts per day10A CFU; lactobacillus acidophilus 2.0 × 1010A CFU; lactobacillus paracasei 2.0X 1010A CFU; 2g of fructo-oligosaccharide; 6g of polydextrose; 2g of xylo-oligosaccharide; 20g of medium chain triglyceride; vitamin B 110 mg; vitamin B 22 mg; vitamin B 610 mg; vitamin B1210μg。
The preparation method of the probiotic solid beverage comprises the following steps: mixing probiotics, vitamins and part of polydextrose according to the content to obtain premix A, mixing the rest polydextrose, xylooligosaccharide, fructooligosaccharide and medium-chain triglyceride to obtain premix B, and uniformly mixing the premix A and the premix B.
Example 2.
A probiotic solid beverage for construction personnel in sealed environment comprises Lactobacillus gasseri 2.5 × 10 per day10A CFU; lactobacillus acidophilus 2.5X 1010A CFU; lactobacillus paracasei 2.0X 1010A CFU; 2g of fructo-oligosaccharide; 5g of polydextrose; 2g of xylo-oligosaccharide; 18g of medium chain triglycerides; vitamin B 18 mg; vitamin B 22 mg; vitamin B 610 mg; vitamin B12100 μ g. The preparation method is the same as example 1.
Example 3.
A probiotic solid beverage for construction personnel in sealed environment comprises Lactobacillus gasseri 2.0 × 10 in parts per day10A CFU; lactobacillus acidophilus 2.0 × 1010A CFU; lactobacillus paracasei 2.0X 1010A CFU; 1.5g of fructo-oligosaccharide; 7g of polyglucose; 1.5g of xylo-oligosaccharide; 24g of medium chain triglycerides; vitamin B 110 mg; vitamin B 22 mg; vitamin B 610 mg; vitamin B12100 μ g. Preparation methodThe procedure is as in example 1.
Example 4.
A probiotic solid beverage for construction personnel in sealed environment comprises Lactobacillus gasseri 1.0 × 10 per day10A CFU; lactobacillus acidophilus 1.0 × 1010A CFU; lactobacillus paracasei 1.0X 1010A CFU; 1g of fructo-oligosaccharide; 6g of polydextrose; 2g of xylo-oligosaccharide; 20g of medium chain triglyceride; vitamin B 110 mg; vitamin B 24 mg; vitamin B 610 mg; vitamin B12100 μ g. The preparation method is the same as example 1.
First, testing the nutrition quality and safety of probiotic solid beverage
1. The test principle is as follows: the detection of the nutritional index, the physicochemical index, the microbial index and the sensory index of the product is strictly carried out according to the calculation of GB 28050 and the execution of GB 7101 solid beverage.
2. The test method comprises the following steps:
2.1 recruiting subjects: 100 workers who are carrying out the project of the closed environment engineering are recruited, the work and rest time, the working environment and the sanitary condition of all the selected subjects are basically kept consistent, and the diet and the living places are all provided by construction units in a unified way. Inclusion criteria were: 1) the health male fills out a comprehensive health score questionnaire before study and passes through routine physical examination; 2) executing construction operation in a closed environment; 3) consented to and received study intervention and follow-up monitoring. Exclusion criteria: 1) executing finance, purchasing, logistics support and the like without entering construction personnel in the closed environment; 2) persons with chronic physical and mental disorders; 3) operators cannot participate in the closed environment in the whole process during temporary borrowing or research; 4) people taking any medicine or frequently taking any vitamin, microelement supplement or health food in nearly 3 months; 5) disagreement or intolerance to the dietary regimen prescribed by the investigator or to the allocated intervention. Subjects follow the voluntary principle, sign informed consent, and can quit in the whole course if adverse conditions occur in the research process.
2.2 experimental grouping:
and (3) personnel grouping: according to the difference of the work types of tested units, a layered random grouping method is adopted to randomly divide the tested units into A, B groups, 50 persons are respectively arranged in each group, and the number of the work types among the groups is ensured to be basically consistent.
Nutrient supply grouping: control group: high calcium and zinc milk
Test groups: probiotic solid beverage + high calcium zinc milk of example 4
Wherein each bag of high calcium and zinc milk contains 227ml of protein 7.5g, fat 8.0g, carbohydrate 8.5g, calcium 375mg and zinc 3.0 mg. The high calcium and zinc milk is purchased from Beijing three-component food products GmbH.
2.3 intervention method: randomly distributing A, B corresponding subjects to the control group and the test group, wherein the group A is supplied with nutrition as the control group; group B nutritional supplies were the test groups. The subjects in group A drink 1 bag of high calcium and zinc milk of the control group each time for 2 times per day; the subjects in group B drunk 1 bag of high calcium and zinc milk plus the probiotic solid beverage of example 4 each time, 2 times per day; both nutritional supplies were taken with meals at breakfast and dinner for 12 weeks.
2.4 Observation index and measuring method
2.4.1 basic case: the number of clinical trial persons and the loss rate are recorded, and the height, the weight, the BMI, the smoking, the drinking and other conditions of the two groups of the trial persons are compared.
2.4.2 diet status: the levels of energy, protein, carbohydrate, fat, calcium, zinc intake before and after intervention were recorded for the test and control groups.
2.4.3 subjective fatigue score: before intervention and at the follow-up time of every 4 weeks, the fatigue degree of a subject is evaluated by adopting a fatigue rating scale-14 (FS-14), wherein the scale is divided into two parts of physical fatigue (1-8 questions) and mental fatigue (9-14 questions), the 10 th, 13 th and 14 th questions are reverse scores, namely, the answer is yes, the score is 0, the answer is no, the score is 1, other questions are forward scores, and the higher the score is, the more the fatigue degree is.
2.4.4 analysis of human body composition: before intervention and the next day after 12 weeks of intervention, indexes such as body fat rate, body water, intracellular and extracellular water, phase angle, waist-hip ratio and the like of a subject are detected by using a BODYSTAT quadrscan 4000 portable body composition analyzer.
3. Evaluation of clinical Effect
3.1 basic case
A total of 97 completed the study with a loss rate of 3%, with 50 in the control group and 47 in the test group. The baseline data showed no significant differences in age, height, weight, BMI, etc. (p > 0.05) between the groups (see Table 1).
TABLE 1 basic conditions of the two groups of subjects
3.2 diet status
There were no significant differences in energy, protein, carbohydrate, fat intake levels (p > 0.05) between the two groups before and after intervention, no statistical difference in calcium and zinc intake levels before intervention, and no statistical difference between groups (p > 0.05) at 12 weeks after intervention (p < 0.05).
TABLE 2 dietary energy and nutrient profile of two groups of subjects
Note: p is < 0.05 compared to before the start of the intervention; p < 0.01 compared to before the start of the intervention.
3.3FS-14 subjective fatigue score results
The two groups have no significant difference in body fatigue, mental fatigue and total fatigue score before the intervention of subjective fatigue score condition. In the aspect of body fatigue, the two groups at the end of the 12-week test are obviously reduced (p is less than 0.05) compared with the groups before intervention, the reduction effect of the test group is more obvious compared with the control group, and no statistical difference exists between other groups and in-group comparison. The test group showed a significant decrease (p < 0.05) in total fatigue score after 12 weeks of intervention compared to both pre-intervention and control groups. See table 3 for details.
TABLE 3 comparison of subjective fatigue scores for two groups of FS-14
Note: p is < 0.05 compared to before the start of the intervention; p < 0.01 compared to before the start of the intervention.
3.4 results of analysis of human body composition
The body fat rate, the body water content, the intracellular and extracellular fluids, the phase angle and the waist and hip of the control group have no statistical difference (p is more than 0.05) before and after intervention, the body fat rate of the test group is obviously reduced (p is less than 0.05) after 12 weeks of intervention compared with that of the control group before the intervention, and other indexes have no statistical significance (p is more than 0.05) compared with that of the control group before the intervention. See table 4 for details.
TABLE 4 comparison of two sets of body composition indicators
Second, sensory evaluation
The probiotic solid beverages prepared in examples 1, 2 and 3 were subjected to sensory evaluation, and 20 laboratory workers form an evaluation group, wherein specific evaluation indexes are tissue state, flavor and smell, mouthfeel and reconstitution property, and the evaluation standards are as follows:
organization (1-10 points, higher score better organization preference);
taste smell (1-10 points, the higher the score, the better the whole flavor);
mouthfeel (1-10 points, the higher the score, the better the overall flavor preference);
reconstitution (1-10 points, the higher the score, the better the reconstitution)
The results are shown in FIG. 2. As is clear from fig. 2, the texture state and taste and flavor evaluation results of examples 1, 2 and 3 were comparable, and no bad sensory feeling was observed. Overall mouthfeel example 1 was superior to examples 2 and 3; impulse examples 1 and 2 were comparable, and the panel was more inclined to example 1 than to example 3.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some of the technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
1. The probiotic solid beverage for construction personnel in a closed environment is characterized by comprising 15-25g of medium-chain triglyceride, 8-15g of prebiotics, 300-800 hundred million CFU of probiotics and 10-25mg of vitamins in parts per day.
2. The probiotic solid beverage for the closed environment constructor according to claim 1, which comprises 18-22g of medium chain triglyceride, 9-12g of prebiotics, 300-800 hundred million CFU of probiotics and 17-23mg of vitamin in daily portion.
3. The probiotic solid beverage for the closed environment constructor according to the claim 1, which comprises 20g of medium chain triglyceride, 10g of prebiotics, 600 hundred million CFU of probiotics and 22mg of vitamin in daily portion.
4. The probiotic solid beverage for the closed environment constructors according to claim 1, wherein the fat in the medium chain triglyceride is more than or equal to 70.0 g/100 g, the caprylic acid (C8:0) accounts for more than or equal to 50.0 percent of the total fat, and the capric acid (C10:0) accounts for more than or equal to 25.0 percent of the total fat; the water content is less than or equal to 2.0 percent.
5. The probiotic solid beverage for the construction personnel in the closed environment according to claim 1, wherein the prebiotics are one or more of fructo-oligosaccharide, xylo-oligosaccharide and polydextrose.
6. The probiotic solid beverage for the closed environment constructor according to claim 1, wherein the probiotics comprise lactobacillus acidophilus, lactobacillus gasseri and lactobacillus paracasei.
7. The probiotic solid beverage for the construction personnel in the closed environment according to claim 1, wherein the vitamin is vitamin B1Vitamin B2Vitamin B6Vitamin B12One or more of (a).
8. The probiotic solid beverage for the construction personnel in the closed environment according to claim 1, which is characterized by comprising the following components in parts per day: 20g of medium chain triglyceride, 200 hundred million CFU of Lactobacillus gasseri, 200 hundred million CFU of Lactobacillus acidophilus, 200 hundred million CFU of Lactobacillus paracasei, 2g of fructo-oligosaccharide, 6g of polydextrose, 2g of xylo-oligosaccharide and vitamin B110mg of vitamin B22 mg; vitamin B610 mg; vitamin B12 100μg。
9. The method for preparing probiotic solid beverage for construction personnel in closed environment according to claim 8, which comprises the steps of premixing and mixing, wherein the premixing comprises mixing probiotics, vitamins and part of polydextrose according to content to obtain premix A, and mixing the rest polydextrose, xylooligosaccharide, fructooligosaccharide and medium chain triglyceride to obtain premix B; the mixing is to uniformly mix the premix A and the premix B.
10. The probiotic solid beverage for the construction personnel in the closed environment according to any one of claims 1 to 8 or the preparation method according to claim 9, and the probiotic solid beverage is applied to food, health care products and medicines.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110117866.0A CN113229503A (en) | 2021-01-28 | 2021-01-28 | Probiotic solid beverage for construction personnel in closed environment and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110117866.0A CN113229503A (en) | 2021-01-28 | 2021-01-28 | Probiotic solid beverage for construction personnel in closed environment and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113229503A true CN113229503A (en) | 2021-08-10 |
Family
ID=77130238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110117866.0A Pending CN113229503A (en) | 2021-01-28 | 2021-01-28 | Probiotic solid beverage for construction personnel in closed environment and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113229503A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
CN109287920A (en) * | 2018-09-14 | 2019-02-01 | 安吉艾格赛思生物科技有限公司 | A kind of solid beverage and preparation method thereof of multicomponent complex and multi-joint probiotics |
-
2021
- 2021-01-28 CN CN202110117866.0A patent/CN113229503A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
CN109287920A (en) * | 2018-09-14 | 2019-02-01 | 安吉艾格赛思生物科技有限公司 | A kind of solid beverage and preparation method thereof of multicomponent complex and multi-joint probiotics |
Non-Patent Citations (2)
Title |
---|
宋茂清 编著: "《益生剂及其功效》", 30 November 2018, 科学技术文献出版社 * |
许豪文 编著: "《运动生物化学概论》", 30 September 2001, 高等教育出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Markowiak et al. | Effects of probiotics, prebiotics, and synbiotics on human health | |
Kim et al. | Effects of the brown seaweed Laminaria japonica supplementation on serum concentrations of IgG, triglycerides, and cholesterol, and intestinal microbiota composition in rats | |
Owczarek et al. | Diet and nutritional factors in inflammatory bowel diseases | |
Douglas et al. | Probiotics and prebiotics in dietetics practice | |
Mitsou et al. | Effect of banana consumption on faecal microbiota: a randomised, controlled trial | |
US9725585B2 (en) | Composition of soluble indigestible fibers and of eukaryotic organisms with a polysaccharide wall, used in the well-being field | |
US20100291050A1 (en) | Nutritional Compositions for Reducing Oxidative Damage | |
CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
WO2019153334A1 (en) | Complex prebiotics regulating human intestinal function and use thereof | |
Li et al. | In-vitro digestion by simulated gastrointestinal juices of Lactobacillus rhamnosus cultured with mulberry oligosaccharides and subsequent fermentation with human fecal inocula | |
Noori et al. | Investigation of potential prebiotic activity of rye sprout extract | |
CN117770454A (en) | Nutritional composition for reducing intestinal pathogens | |
Oh et al. | Efficacy of a synbiotic containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in elderly patients with irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial | |
Pansai et al. | Effects of dragon fruit oligosaccharides on immunity, gut microbiome, and their metabolites in healthy adults–A randomized double-blind placebo controlled study | |
Melekoglu et al. | Dietary strategies for gut-derived protein-bound uremic toxins and cardio-metabolic risk factors in chronic kidney disease: A focus on dietary fibers | |
da Cruz et al. | Probiotics and Prebiotics in Foods: Challenges, Innovations, and Advances | |
CN113229503A (en) | Probiotic solid beverage for construction personnel in closed environment and preparation method and application thereof | |
Sen et al. | Fruit waste pectin in enhancing the establishment of probiotic bacteria | |
Wang et al. | Novel prospective of wild mushroom polysaccharides as potential prebiotics | |
Dahiya et al. | Inclusion of dietary-fibers in nutrition provides prebiotic substrates to probiotics for the synthesis of beneficial metabolites SCFA to sustain gut health minimizing risk of IBS, IBD, CRC | |
CN114946954A (en) | Solid beverage of probiotic compound composition containing traditional Chinese medicine components and preparation method | |
US11103543B2 (en) | Composition for recovering from fatigue and/or preventing fatigue accumulation | |
Ayyadurai et al. | Beneficial role of fermented rice in healthy lifestyle | |
Vinayak et al. | Prebiotics for probiotics | |
TWI835021B (en) | Probiotic composition and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |